6 completed, 2 terminated, 1 suspended, 1 unknown. 6 Phase 1, 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 4, Suspended 1, Terminated 1 |
| Phase 2 | 6 | Completed 4, Suspended 1, Terminated 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Humanigen, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma Cyclophosphamide, Fludarabine, Lenzilumab - Relapsed/Refractory Large B-cell Lymphoma | Phase 1 | Terminated | Kite, A Gilead Company | 6 | 2020-05-26 | 2024-03-04 |
| Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 Lenzilumab, Standard of Care - Coronavirus Disease 2019 (COVID-19) Pneumonia | Phase 3 | Unknown | Humanigen, Inc. | 520 | 2020-05-05 | 2021-03-03 |
| A Trial of KB004 in Patients With Glioblastoma KB004 - Glioblastoma | Phase 1 | Completed | Olivia Newton-John Cancer Research Institute | 12 | 2017-12-05 | 2021-11-04 |
| Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML) lenzilumab - Chronic Myelomonocytic Leukemia (CMML) | Phase 1 | Completed | Humanigen, Inc. | 15 | 2016-07-01 | 2020-02-28 |
| Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment KB001-A, Placebo Comparator - Cystic Fibrosis | Phase 2 | Completed | Humanigen, Inc. | 182 | 2012-12-01 | 2015-01-14 |
| Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids Anti-GM-CSF Monoclonal Antibody 400mg, Placebo - Moderate-to-Severe Asthma | Phase 2 | Completed | Humanigen, Inc. | 160 | 2012-07-01 | 2015-02-02 |
| Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) KB004, Monoclonal Antibody - Myelodysplastic Syndrome (MDS), Myelofibrosis (MF) | Phase 1 / Phase 2 | Suspended | Humanigen, Inc. | 120 | 2010-09-01 | 2015-11-17 |
| Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis KB003, Placebo Comparator - Rheumatoid Arthritis | Phase 2 | Terminated | Humanigen, Inc. | 9 | 2010-01-01 | 2014-06-09 |
| Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa KB001, Placebo - Pseudomonas Aeruginosa, Ventilator Associated Pneumonia | Phase 1 / Phase 2 | Completed | Humanigen, Inc. | 36 | 2008-04-01 | 2009-07-31 |
| Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa KB001, Placebo - Cystic Fibrosis | Phase 1 / Phase 2 | Completed | Humanigen, Inc. | 27 | 2008-03-01 | 2014-06-09 |
Pseudomonas Infections (3) · Cystic Fibrosis (2) · Arthritis, Rheumatoid (1) · Asthma (1) · COVID-19 (1) · Cytokine Release Syndrome (1) · Glioblastoma (1) · Leukemia (1) · Leukemia, Myelomonocytic, Chronic (1) · Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1) · Neoplasms (1) · Pneumonia (1) · Pneumonia, Ventilator-Associated (1) · Primary Myelofibrosis (1)
lenzilumab (4) · KB004 (2) · Antibodies, Monoclonal (1) · Cyclophosphamide (1) · Standard of Care (1) · axicabtagene ciloleucel (1) · fludarabine (1)
United States (8) · Australia (4) · France (2) · Brazil (1) · Israel (1) · New Zealand (1) · Poland (1) · Ukraine (1) · United Kingdom (1)
Nestor A. Molfino, MD, MSc (2) · Cameron Durrant, MD (1) · Carlos Milla, MD (1) · Hui Gan (1) · Morgan Lam (1) · Nestor A. Molfino, MD, MSC (1) · Nestor A. Molfino, MD., MSc (1) · Prof. Jean Chastre (1)
PMID 24019259, PMID 26739717, PMID 27736729, PMID 33153629, PMID 33673929, PMID 33972949, PMID 34863332, PMID 35793833
2019 (1)